Approval Package for:

APPLICATION NUMBER:

NDA 022410/S-011

Trade Name: SUBOXONE

Generic Name: Buprenorphine Hydrochloride; Naloxone Hydrochloride

Sponsor: Reckitt Benckiser Pharmaceuticals, Inc.

Approval Date: 08/08/2013

Indications: SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.
## CONTENTS

<table>
<thead>
<tr>
<th>Reviews / Information Included in this NDA Review.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Other Action Letters</td>
</tr>
<tr>
<td>Labeling</td>
</tr>
<tr>
<td>Summary Review</td>
</tr>
<tr>
<td>Officer/Employee List</td>
</tr>
<tr>
<td>Office Director Memo</td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
</tr>
<tr>
<td>Medical Review(s)</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
</tr>
<tr>
<td>Environmental Assessment</td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
</tr>
<tr>
<td>Other Review(s)</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
NDA 022410/S-011

APPROVAL LETTER
Dear Ms. Dimri:

Please refer to your Supplemental New Drug Application (sNDA), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

<table>
<thead>
<tr>
<th>NDA</th>
<th>Supplement</th>
<th>Drug Product</th>
<th>Dated</th>
<th>Received</th>
</tr>
</thead>
<tbody>
<tr>
<td>18401</td>
<td>S-019</td>
<td>Buprenex® (buprenorphine HCl) Injection</td>
<td>March 15, 2013</td>
<td>March 18, 2013</td>
</tr>
<tr>
<td>20732</td>
<td>S-009</td>
<td>Subutex® (buprenorphine HCl) Sublingual Tablet</td>
<td>March 15, 2013</td>
<td>March 18, 2013</td>
</tr>
<tr>
<td>20733</td>
<td>S-011</td>
<td>Suboxone® (buprenorphine HCl/ naloxone HCl) Sublingual Tablet</td>
<td>March 15, 2013</td>
<td>March 18, 2013</td>
</tr>
</tbody>
</table>

These “Changes Being Effected” supplements provide to register post approval drug substance changes made to the manufacture of drug substance Buprenorphine HCl, in DMF 12412.

We have completed our review of these supplemental new drug applications. These supplements are approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call LCDR Luz E Rivera, Regulatory Project Manager, at (301) 796-4013.
Sincerely,

[See appended electronic signature page]

Ramesh Raghavachari, Ph.D.
Acting Branch Chief, Branch IX
Division of New Drug Quality Assessment III
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAMESH RAGHAVACHARI
08/08/2013

Reference ID: 3354373
APPLICATION NUMBER:
NDA 022410/S-011

CHEMISTRY REVIEW(S)
Chemistry Review:

1. Division: ONDQA-DAAAP
2. NDA Number: (a) 20-733 S011, (b) 20-732 S009, (c) 18-401 S019, (d) 22-410 S011

3. Name and Address of Applicant:
   RECKITT BENCKISER
   10710 Midlothian Turnpike
   Richmond VA 23235

4. Supplement(s): CBE-0
   Number: Refer to NDA number
   Date(s): 02/25/2013
   PDUFA Date: 09/18/2013

5. Name of Drug:
   (a) Suboxone® (buprenorphine HCl/Naloxone HCl), sublingual tablets
   (b) Subutex® (buprenorphine HCl), sublingual tablets,
   (c) Buprenex® injection (buprenorphine HCl)
   (d) Suboxone® (buprenorphine HCl/Naloxone HCl)
   Sublingual Film

6. Nonproprietary name:
   Buprenorphine HCl

7. Supplement Provides for: incorporation of CMC changes made to manufacture of drug substance Buprenorphine HCl, in DMF 12412.

8. Amendment(s): 

9. Pharmacological Category:
   mu-opioid receptor partial agonist and a kappa-opioid receptor antagonist

10. How Dispensed:
    Rx

11. Related Documents: DMF12412

12. Dosage Form: Refer to Name of Drug

13. Potency: 2 mg and 8 mg

14. Chemical Name and Structure:
   Buprenorphine HCl: 6 (2S)-2-[17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6α,14-ethano-14α-morphinan-7α-yl]-3,3dimethylbutan-2-ol hydrochloride; CAS: [53152-21-9]; C29H41NO4·HCl; MW = 504.10

   Naloxone HCl: 17-Allyl-4, 5 α -epoxy-3, 14-dihydroxymorphinan-6-one hydrochloride dihydrate; CAS: [357-08-4]; C19H21NO4 • HCl • 2H2O; MW = 399.87

15. Comments:
   - Incorporation of CMC changes made to drug substance, buprenorphine HCl in DMF 12412 to NDA
   - LOA provided 3/10/2013

16. Conclusion: This supplement is recommended for approval from CMC perspective

17. Name: Erika E. Englund, Ph.D., Chemist
    Signature: Date:

18. Concurrence: Ramesh Raghavachari, Ph.D., Acting Branch Chief, Br., IX, ONDQA
    Signature: Date:

---

5 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIKA E ENGLUND
08/07/2013

RAMESH RAGHAVACHARI
08/07/2013
APPLICATION NUMBER:
NDA 022410/S-011

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
NDAs 18401/ S-019, 20732/S-009, 20733/ S-011 & 22410/ S-011 bundle

GENERAL CORRESPONDENCE

Reckitt Benckiser Pharmaceuticals, Inc.
Attention: Vanity Dimri, RAC, ASQ, CQA
Regulatory Affairs
10710 Midlothian Turnpike
Richmond VA 23235

Dear Ms. Dimri:

Please refer to your supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

<table>
<thead>
<tr>
<th>NDA</th>
<th>Supplement</th>
<th>Drug Product</th>
<th>Dated</th>
<th>Received</th>
</tr>
</thead>
</table>

The March 22, 2013 Acknowledgement letter did not include sNDA 22410/ S-011, dated and received March 15, 2013. These “Changes Being Effected” supplements propose to register post approval drug substance changes.

Unless we notify you within 60 days of the receipt date that the applications are not sufficiently complete to permit a substantive review, we will file the applications on the new date of May 15, 2013 not May 27, 2013, in accordance with 21 CFR 314.101(a). If the applications are filed, the user fee goal date will be September 15, 2013 not September 18, 2013 as was indicated on the March 22, 2013 acknowledgement letter.
If you have any questions, call LCDR Luz E Rivera, Regulatory Project Manager, at (301) 796 4013.

Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D.
Acting Branch Chief, Branch IX
Division of New Drug Quality Assessment III
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAMESH RAGHAVACHARI
04/02/2013